Table 2

 Details of the patients who underwent “classic” and “light” treatment

PatientAgeSexInitial visual acuityNo of letters gained/lostInitial foveal thicknessFinal foveal thicknessChange in foveal thickness on OCTReduction/resolution of CSMO on slit lampReduction/resolution of leakage on FARe-treatment
CSMO, clinically significant macular oedema ; FA, fluorescein angiography.
(A) “Classic” treatment group
161M20/10015510367DecreasedYesYes
275F20/32−1400433NoNoNoYes (1 year)
354M20/251236290IncreasedNoYes
468F20/62.514384298DecreasedYesYes
560M20/329275237DecreasedYesYes
666F20/25−8324306NoYesYes
768F20/25−2216340IncreasedNoYesYes (1 year)
855M20/50−9555306DecreasedYesYesYes (6 months)
961M20/200292284NoYesYes
1064M20/252241240NoYesYes
1176M20/252322406IncreasedNoNoYes (1 year)
1258M20/4010291237DecreasedYesYes
1362M20/400500218DecreasedYesNo
1464F20/250499412DecreasedYesNoYes (1 year)
(B) “Light” treatment group
161M20/32−4449550IncreasedNoYesYes (6 months)
259M20/20−1266400IncreasedNoNoYes (1 year)
356F20/402278253NoNoYes
460M20/255356278DecreasedNoYes
560M20/326306240DecreasedYesNo
663M20/200NANANANoNo
756M20/201237234NoYesYes
868F20/25−8345428IncreasedNoNoYes (6 months)
963F20/3210258173DecreasedYesYes
1055M20/62.56588268DecreasedYesYesYes (6 months)
1174F20/401305501IncreasedNoNoYes (1 year)
1276M20/32−15371579IncreasedNoNoYes (1 year)
1377M20/32−1301271DecreasedNoYes
1458F20/4011211183DecreasedYesYes
1565M20/25−1320322NoNoYes